Q2 2025 Management View Chirag K. Patel, Co-Founder and Co-CEO, highlighted "another consecutive quarter of strong performance and growth with revenues of $720 million and adjusted EBITDA of $184 ...

Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its ...

Metsera will present significant clinical data from its Phase 1/2 trial of MET-097i, a next-generation GLP-1 receptor agonist, at a prominent scientific conference, enhancing the company's ...

Metsera, a biotech focused on obesity drugs that came out of stealth this year, said Tuesday that it is partnering with drug manufacturer Amneal Pharmaceuticals to produce injectable and oral ...

Metsera said the treatment has a half life of about 16 days. The current GLP-1 drugs on the market, such as Wegovy and Zepbound, are dosed weekly, so a monthly option could be more convenient and ...

Metsera has $187.6 million of cash and cash equivalents, according to the filings. Its offering was led by Bank of America Corp., Goldman Sachs Group Inc., Evercore Inc., Guggenheim Securities ...

View Metsera, Inc. MTSR stock quote prices, financial information, real-time forecasts, and company news from CNN.

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin ...

Metsera will present clinical data from MET-097i’s Phase 1/2 clinical trial in two presentations, including change in body weight and tolerability data after twelve weekly doses and after a ...